No profile data available.
Ironwood Pharmaceuticals, Inc. (IRWD) is a healthcare company in the digestive system treatment drugs industry, based in Boston, United States, with about 100 full-time employees.
It reported revenue of $296.15 million for fiscal year 2025, down 15.7% from fiscal year 2024, and net income of $24.02 million. United States was its largest region in fiscal year 2025, with 98% of revenue. Its market capitalization was $631.22 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
Ironwood Pharmaceuticals reported $296.15 million in revenue for fiscal year 2025, down 15.7% from $351.41 million in fiscal year 2024.
United States: 98% of revenue by region in fiscal year 2025, followed by Rest of World (2%).
$631.22 million as of October 9, 2026.
Listed companies of a similar size in the same industry (digestive system treatment drugs) include Spyre Therapeutics, Inc. (SYRE), Abivax Société Anonyme (ABVX), Phathom Pharmaceuticals, Inc. (PHAT), Palisade Bio, Inc. (PALI).